Alnylam Pharmaceuticals (ALNY) Accumulated Depreciation & Amortization (2017 - 2025)
Historic Accumulated Depreciation & Amortization for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Q4 2025 value amounting to $322.7 million.
- Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization rose 1935.76% to $322.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $322.7 million, marking a year-over-year increase of 1935.76%. This contributed to the annual value of $322.7 million for FY2025, which is 1935.76% up from last year.
- Per Alnylam Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $322.7 million for Q4 2025, which was up 1935.76% from $270.4 million recorded in Q4 2024.
- In the past 5 years, Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $322.7 million in Q4 2025 and a low of $140.4 million during Q4 2021
- Over the past 5 years, Alnylam Pharmaceuticals' median Accumulated Depreciation & Amortization value was $223.1 million (recorded in 2023), while the average stood at $226.0 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 3456.54% in 2021, then surged by 1935.76% in 2025.
- Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $140.4 million in 2021, then increased by 23.53% to $173.4 million in 2022, then grew by 28.61% to $223.1 million in 2023, then increased by 21.2% to $270.4 million in 2024, then increased by 19.36% to $322.7 million in 2025.
- Its last three reported values are $322.7 million in Q4 2025, $270.4 million for Q4 2024, and $223.1 million during Q4 2023.